

QY	2523	gtgtggggccccgtcggggggggtcccccgaactctcagaacccctgcgtctggccc	2582	PR	23-MAY-1997;	97US-0047501...
Db	2520	gtgtggggccccgtcggggggggtcccccgaactctcagaacccctgcgtctggccc	2579	PR	23-MAY-1997;	97US-0047503...
QY	2583	ccctccaaaggatgaggatgtggccctcgagaaaaactatgccccgcagcttc	2642	PR	23-MAY-1997;	97US-0047581...
Db	2580	ccctccaaaggatgaggatgtggccctcgagaaaaactatgccccgcagcttc	2639	PR	23-MAY-1997;	97US-0047582...
QY	2643	ccagtccaaactgtatggcccgatgcagcaggcaggacacagcaggatcttc	2702	PR	23-MAY-1997;	97US-0047583...
Db	2640	ccagtccaaactgtatggcccgatgcagcaggcaggacacagcaggatcttc	2699	PR	23-MAY-1997;	97US-0047584...
QY	2703	caaccacatcgctgtggccaggaaactatgtggccaaatatatttcac	2762	PR	23-MAY-1997;	97US-0047585...
Db	2700	caaccacatcgctgtggccaggaaactatgtggccaaatatatttcac	2759	PR	23-MAY-1997;	97US-0047590...
QY	2763	taactc 2768		PR	23-MAY-1997;	97US-0047596...
Db	2760	taactc 2765		PR	23-MAY-1997;	97US-0047597...
RESULT 4						
ID	AAV59691	standard; DNA; 2779 BP.	XX	PR	23-MAY-1997;	97US-0047598...
AC	AAV59691;		XX	PR	23-MAY-1997;	97US-0047599...
DE	Human secreted protein gene 181 clone HAFAU18.		XX	PR	23-MAY-1997;	97US-0047610...
KW	Human; secreted protein; fusion protein; gene therapy; protein therapy; diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia; developmental abnormality; foetal deficiency; blood; allergy; renal; ds; immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma; inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS; cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus; osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion; endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.		XX	PR	23-MAY-1997;	97US-0047613...
OS	Homo sapiens.		XX	PR	23-MAY-1997;	97US-0047632...
PN	W09839448-A2.		XX	PR	06-JUN-1997;	97US-0048964...
PD	11-SEP-1998.		XX	PR	13-JUN-1997;	97US-0049610...
PF	06-MAR-1998;	98WO-US04493.	XX	PR	08-JUL-1997;	97US-0051926...
PR	02-OCT-1997;	97US-0061060.	XX	PR	18-AUG-1997;	97US-0055724...
PR	07-MAR-1997;	97US-0038621.	XX	PR	22-AUG-1997;	97US-0056631...
PR	07-MAR-1997;	97US-0040161.	XX	PR	22-AUG-1997;	97US-0056632...
PR	07-MAR-1997;	97US-0040162.	XX	PR	22-AUG-1997;	97US-0056872...
PR	07-MAR-1997;	97US-0040163.	XX	PR	22-AUG-1997;	97US-0056874...
PR	07-MAR-1997;	97US-0040133.	XX	PR	22-AUG-1997;	97US-0056637...
PR	07-MAR-1997;	97US-004034.	XX	PR	22-AUG-1997;	97US-0056662...
PR	07-MAR-1997;	97US-0040336.	XX	PR	22-AUG-1997;	97US-0056664...
PR	07-MAR-1997;	97US-0040326.	XX	PR	22-AUG-1997;	97US-0056862...
PR	11-APR-1997;	97US-0043311.	XX	PR	22-AUG-1997;	97US-0056864...
PR	11-APR-1997;	97US-0043312.	XX	PR	22-AUG-1997;	97US-0056871...
PR	11-APR-1997;	97US-0043313.	XX	PR	22-AUG-1997;	97US-0056872...
PR	11-APR-1997;	97US-0043314.	XX	PR	22-AUG-1997;	97US-0056879...
PR	11-APR-1997;	97US-0043318.	XX	PR	22-AUG-1997;	97US-0056880...
PR	11-APR-1997;	97US-0043369.	XX	PR	22-AUG-1997;	97US-0056881...
PR	11-APR-1997;	97US-0043571.	XX	PR	22-AUG-1997;	97US-0056882...
PR	11-APR-1997;	97US-0043576.	XX	PR	22-AUG-1997;	97US-0056884...
PR	11-APR-1997;	97US-0043578.	XX	PR	22-AUG-1997;	97US-0056885...
PR	11-APR-1997;	97US-0043580.	XX	PR	22-AUG-1997;	97US-0056887...
PR	23-MAY-1997;	97US-0047592.	XX	PR	22-AUG-1997;	97US-0056889...
PR	23-MAY-1997;	97US-0047590.	XX	PR	22-AUG-1997;	97US-0056893...
PR	05-SEP-1997;	97US-0057650.	XX	PR	22-AUG-1997;	97US-0057651...
PR	05-SEP-1997;	97US-0057761.	XX	PR	22-AUG-1997;	97US-0057761...

AAC60297 ID AAC60297 standard; DNA; 2469 BP.
 XX ID AAC60297 standard; DNA; 2469 BP.
 XX
 AC AAC60297;
 XX
 XX DT 14-FEB-2001 (first entry)
 XX
 DE Human vanilloid receptor like receptor DNA.
 XX VR-L; vanilloid receptor-like receptor; pain; infection; allergy;
 XX mechanical injury; lymphoid tissue; human; ds.
 OS Homo sapiens.
 XX
 PN GB2346882-A.
 XX
 XX PD 23-AUG-2000.
 XX
 PF 02-DEC-1999; 99GB-0028566.
 XX
 PR 08-DEC-1998; 98GB-0027016.
 XX
 XX (MERIT) MERCK SHARP & DOHME LTD.
 XX
 PA (MERIT) MERCK SHARP & DOHME LTD.
 XX
 PI Bonnett TP;
 XX
 DR WPI; 2001-064250/08.
 DR P-PSDB; AAB35622.
 PT New polynucleotide encoding human vanilloid receptor-like receptor for
 PT diagnosing and treating pain, infections, allergies, and cancers.
 XX
 PS Claim 2; Fig 1; 36pp; English.
 XX
 CC The present invention relates to the human vanilloid receptor-like
 CC receptor. This receptor may be used for diagnosing or treating
 CC conditions associated with altered vanilloid receptor-like (VR-L)
 CC receptor expression. It may also be used to treat abnormal conditions
 CC associated with pain. Conditions or diseases that can be diagnosed or
 CC treated include viral, bacterial and fungal infections, allergic
 CC responses, mechanical injury associated with trauma, hereditary
 CC diseases, lymphoma or carcinoma, or other conditions which activate
 CC the genes of the lymphoid tissues.
 XX
 Sequence 2469 BP; 510 A; 724 C; 710 G; 525 T; 0 other;
 SQ

Db	123 ttccagggttggagacatttagatggggccagaagaatgtgtggccacaggaaa	182	Qy	1527 caagtctttcttaacttccctgtgtatctgtatctacatgttcacccgtttgc	1586
Qy	447 gctgtatgtttggacggggcgtccatggatcagttcccccggggaggacggaa	506	Db	1263 aagtctttcttaacttccctgtgtatctgtatctacatgttcacccgtttgc	1322
Db	183 gctgtatgtttggacggggcgtccatggatcagttcccccggggaggacggaa	242	Qy	1587 ctaccatcaggttacccgtggaaacccgggggggggggggggggggggggg	1646
Qy	507 attccggccctcagataaagagtcactcaactcaactcaactcaactcaact	566	Db	1323 ctaccatcaggttacccgtggaaacccgggggggggggggggggggggggg	1382
Db	243 attccggccctcagataaagagtcactcaactcaactcaactcaactcaact	302	Qy	1647 ctccatgtgtggggccacatcttacccgttagggggatctactccctgtgg	1705
Qy	567 ggatccaaacgatttgaccggatgggggggggggggggggggggggggggg	626	Db	1383 ctccatgtgtggggccacatcttacccgttagggggatctactccctgtgg	1442
Db	303 ggatccaaacgatttgaccggatgggggggggggggggggggggggggggg	362	Qy	1707 ccagctgtgttactctggggccacgtttccatgtgtatctgtatctgtat	1766
Qy	627 ggatccaaacgatttgaccggatgggggggggggggggggggggggggggg	686	Db	1443 coagctgtgttactctggggccacgtttccatgtgtatctgtatctgtat	1502
Db	363 ggatccaaacgatttgaccggatgggggggggggggggggggggggggggg	422	Qy	1767 ctthaaatcttcttctgttccagggccatcttacccgttagggggatctt	1826
Qy	687 atacacaggggttccacacgtaaagacgtgtgtgtgtgtgtgtgtgtgtgt	746	Db	1503 cttyaaatcccttctgttccagggccatcttacccgttagggggatctt	1562
Db	423 atacacaggggttccacacgtaaagacgtgtgtgtgtgtgtgtgtgtgtgt	482	Qy	1827 ctggccatcgt	1886
Qy	747 ccggccatcgt	806	Db	1563 ctggccatcgt	1622
Db	483 ccggccatcgt	542	Qy	1887 ctgtgttactatacgtgtgttccagccacagcatatcgtgtatccatgtat	1946
Qy	807 gcccctgtgtaaatggccagggtgtgtgtgtgtgtgtgtgtgtgtgtgt	866	Db	1623 ctgtgttactatacgtgtgttccagccacagcatatcgtgtatccatgtat	1682
Db	543 gcccctgtgtaaatggccagggtgtgtgtgtgtgtgtgtgtgtgtgtgt	602	Qy	1947 9gtcatctgt	2006
Qy	867 ccggccatcgt	926	Db	1683 9gtcatctgt	1742
Db	603 ccggccatcgt	662	Qy	2007 cgctgttagccctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt	2066
Qy	927 ccggccatcgt	986	Db	1743 cgctgttagccctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt	1802
Db	663 gcatggccgggttccaggccatcttccagaaggccaaaggactgtgtttat	722	Qy	2067 caatggccacaggtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt	2126
Qy	987 tgaggatccctcttgggggttccggatgtgtgtgtgtgtgtgtgtgtgtgt	1046	Db	1803 oaatggccacaggt	1862
Db	723 tgaggatccctcttgggggttccggatgtgtgtgtgtgtgtgtgtgtgtgt	782	Qy	2127 gtacgggtatccggaaaccttcttgggttcaatccatggatggatggatgg	2186
Qy	1047 ggaggatccacccggccggccggccggccggccggccggccggccggccgg	1106	Db	1863 9tacagggttccatgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt	1922
Db	783 ggaggatccacccggccggccggccggccggccggccggccggccggccgg	842	Qy	2187 gttgt	2246
Qy	1107 gcatggccatgt	1166	Db	1923 gttgt	1982
Db	843 gcatggccatgt	902	Qy	2247 cgt	2306
Qy	1167 gttatgt	1226	Db	1983 cgt	2042
Db	903 gttatgt	962	Qy	2307 caatgggttccatgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt	2366
Qy	1227 ccggccatcgt	1286	Db	2043 caacatggccatgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt	2102
Db	963 ccggccatcgt	1022	Qy	2367 ggatggatggatggatggatggatggatggatggatggatggatggatggat	2426
Qy	1287 ttccaggccatcgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt	1346	Db	2103 ggatggatggatggatggatggatggatggatggatggatggatggatggat	2162
Db	1023 ttccaggccatcgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt	1082	Qy	2427 cttggccatcgt	2486
Qy	1347 cgagggtgtatgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt	1406	Db	2223 gaactgggttccatgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt	2282
Db	1083 cgagggtgtatgt	1142	Qy	2547 tggccctcgaaactctcgagaaacctgtgtgtgtgtgtgtgtgtgtgtgtgt	2606
Qy	1407 tgaggatggatggatggatggatggatggatggatggatggatggatggatgg	1466	Db	2283 tggccctcgaaactctcgagaaacctgtgtgtgtgtgtgtgtgtgtgtgtgt	2342
Db	1143 tgaggatggatggatggatggatggatggatggatggatggatggatggatgg	1202			
Qy	1467 aatgt	1526			
Db	1203 aatgt	1262			

XX
DR
XX
PT
PT
PT
PT
XX
PS
XX
CC
XX
SQ

WPI: 1998-506364/43.
P-PSSDB; AAW75021.

New isolated human genes and the secreted polypeptide(s) from the human cDNA clone HARA118 (deposited as clone ATCC 20050) which encodes a secreted human protein. The invention relates to 186 novel genes and their fragment sequences: AAV59511-V59312; amino acid sequences which are useful for preventing, treating or ameliorating conditions e.g. by protein or gene therapy. Also, pathologic conditions can be diagnosed by determining the amount of polypeptides in a sample or by determining the presence of the new polynucleotides. Specific uses are described for polynucleotides, based on which tissues they are most highly expressed (see AAV59511 for described uses).

Claim 1: Page 538-539; 711pp; English.

Sequence 2860 BP; 604 A; 834 C; 815 G; 587 T; 20 other;

Query	Match	Score	DB	Length
QY 2503 gaaacgacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	83.6%; Best Local Similarity	2347.8;	DB 20;	Length 2351;
Db 2161 gagacgacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.9%; Matches	2249;	Pred. No. 0;	Conservative
QY 2663 gaaacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2240	Mismatches	2;
Db 2221 gagacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2280	Indels	0;
QY 2623 tagtgccgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2682	Gaps	0;
Db 2281 tagtgccgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2340		
QY 2683 gacagacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2722		
Db 2341 gacagacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2380		
RESULT 8				
AA207114				
ID AA207114	standard; cDNA;	2351	BP.	
XX				
AC AA207114;				
XX				
DT 08-OCT-1999	(first entry)			
XX				
DE Human vanilloid receptor homologue VANILREP2 encoding cDNA.				
XX				
KW Human; vanilloid receptor homologue; VANILREP2; polymorphic variant; PVR-1; therapy; diagnosis; chronic pain; neuropathic; postoperative; rheumatoid arthritis; neuralgia; algisia; nerve injury; ischaemia; neurodegeneration; stroke; incontinence; inflammatory disorder; ss.				
XX				
OS Homo sapiens.				
XX				
Key	Location/Qualifiers			
FT CDS	5..2299			
FT	/*tag= a			
FT	/product= "VANILREP2"			
FT	/note= "vanilloid receptor homologue"			
XX				
PN W0937765-A1.				
XX				
PD 29-JUL-1999.				
XX				
PF 25-JAN-1999;	99NC-EP00420.			
XX				
PR 20-JAN-1999;	99GB-0001209.			
PR	27-JAN-1998;	98EP-0300549.		
PR	26-OCT-1998;	98GB-0023421.		
PA (SMK) SMITHKLINE BEECHAM PLC.				
XX				
PI Davis JB, Duckworth DM, Hayes PD;				
XX				
DR WPI: 1999-479049/40.				
DR P-PSDB; AAY29469.				
PT New human vanilloid receptor homologues (VANILREP2)				
XX				
PS Claim 9; Page 29-30; 47pp; English.				
XX				
CC The present sequence encodes a human vanilloid receptor homologue, designated VANILREP2. VANILREP2 can be used to diagnose disease or susceptibility to disease related to expression or activity of VANILREP2 polypeptides. VANILREP2 may be used to treat diseases including pain, (for example chronic, neuropathic, postoperative, rheumatoid arthritis), neuralgia, algisia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence, and inflammatory disorders.				
CC Sequence 2351 BP; 486 A; 684 C; 676 G; 505 T; 0 other;				
SQ				
Query	Match	Score	DB	Length
QY 2503 gaaacgacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	83.6%; Best Local Similarity	2347.8;	DB 20;	Length 2351;
Db 2161 gagacgacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.9%; Matches	2249;	Pred. No. 0;	Conservative
QY 2663 gaaacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2240	Mismatches	2;
Db 2221 gagacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2280	Indels	0;
QY 2623 tagtgccgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2682	Gaps	0;
Db 2281 tagtgccgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2340		
QY 2683 gacagacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2722		
Db 2341 gacagacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2380		
RESULT 8				
AA207114				
ID AA207114	standard; cDNA;	2351	BP.	
XX				
AC AA207114;				
XX				
DT 08-OCT-1999	(first entry)			
XX				
DE Human vanilloid receptor homologue VANILREP2 encoding cDNA.				
XX				
KW Human; vanilloid receptor homologue; VANILREP2; polymorphic variant; PVR-1; therapy; diagnosis; chronic pain; neuropathic; postoperative; rheumatoid arthritis; neuralgia; algisia; nerve injury; ischaemia; neurodegeneration; stroke; incontinence; inflammatory disorder; ss.				
XX				
OS Homo sapiens.				
XX				
Key	Location/Qualifiers			
FT CDS	5..2299			
FT	/*tag= a			
FT	/product= "VANILREP2"			
FT	/note= "vanilloid receptor homologue"			
XX				
PN W0937765-A1.				
XX				
PD 29-JUL-1999.				
XX				
PF 25-JAN-1999;	99NC-EP00420.			
XX				
PR 20-JAN-1999;	99GB-0001209.			
PR	27-JAN-1998;	98EP-0300549.		
PR	26-OCT-1998;	98GB-0023421.		
PA (SMK) SMITHKLINE BEECHAM PLC.				
XX				
PI Davis JB, Duckworth DM, Hayes PD;				
XX				
DR WPI: 1999-479049/40.				
DR P-PSDB; AAY29469.				
PT New human vanilloid receptor homologues (VANILREP2)				
XX				
PS Claim 9; Page 29-30; 47pp; English.				
XX				
CC The present sequence encodes a human vanilloid receptor homologue, designated VANILREP2. VANILREP2 can be used to diagnose disease or susceptibility to disease related to expression or activity of VANILREP2 polypeptides. VANILREP2 may be used to treat diseases including pain, (for example chronic, neuropathic, postoperative, rheumatoid arthritis), neuralgia, algisia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence, and inflammatory disorders.				
CC Sequence 2351 BP; 486 A; 684 C; 676 G; 505 T; 0 other;				
SQ				
Query	Match	Score	DB	Length
QY 2503 gaaacgacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	83.6%; Best Local Similarity	2347.8;	DB 20;	Length 2351;
Db 2161 gagacgacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.9%; Matches	2249;	Pred. No. 0;	Conservative
QY 2663 gaaacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2240	Mismatches	2;
Db 2221 gagacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2280	Indels	0;
QY 2623 tagtgccgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2682	Gaps	0;
Db 2281 tagtgccgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2340		
QY 2683 gacagacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2722		
Db 2341 gacagacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2380		
RESULT 8				
AA207114				
ID AA207114	standard; cDNA;	2351	BP.	
XX				
AC AA207114;				
XX				
DT 08-OCT-1999	(first entry)			
XX				
DE Human vanilloid receptor homologue VANILREP2 encoding cDNA.				
XX				
KW Human; vanilloid receptor homologue; VANILREP2; polymorphic variant; PVR-1; therapy; diagnosis; chronic pain; neuropathic; postoperative; rheumatoid arthritis; neuralgia; algisia; nerve injury; ischaemia; neurodegeneration; stroke; incontinence; inflammatory disorder; ss.				
XX				
OS Homo sapiens.				
XX				
Key	Location/Qualifiers			
FT CDS	5..2299			
FT	/*tag= a			
FT	/product= "VANILREP2"			
FT	/note= "vanilloid receptor homologue"			
XX				
PN W0937765-A1.				
XX				
PD 29-JUL-1999.				
XX				
PF 25-JAN-1999;	99NC-EP00420.			
XX				
PR 20-JAN-1999;	99GB-0001209.			
PR	27-JAN-1998;	98EP-0300549.		
PR	26-OCT-1998;	98GB-0023421.		
PA (SMK) SMITHKLINE BEECHAM PLC.				
XX				
PI Davis JB, Duckworth DM, Hayes PD;				
XX				
DR WPI: 1999-479049/40.				
DR P-PSDB; AAY29469.				
PT New human vanilloid receptor homologues (VANILREP2)				
XX				
PS Claim 9; Page 29-30; 47pp; English.				
XX				
CC The present sequence encodes a human vanilloid receptor homologue, designated VANILREP2. VANILREP2 can be used to diagnose disease or susceptibility to disease related to expression or activity of VANILREP2 polypeptides. VANILREP2 may be used to treat diseases including pain, (for example chronic, neuropathic, postoperative, rheumatoid arthritis), neuralgia, algisia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence, and inflammatory disorders.				
CC Sequence 2351 BP; 486 A; 684 C; 676 G; 505 T; 0 other;				
SQ				
Query	Match	Score	DB	Length
QY 2503 gaaacgacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	83.6%; Best Local Similarity	2347.8;	DB 20;	Length 2351;
Db 2161 gagacgacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.9%; Matches	2249;	Pred. No. 0;	Conservative
QY 2663 gaaacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2240	Mismatches	2;
Db 2221 gagacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2280	Indels	0;
QY 2623 tagtgccgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2682	Gaps	0;
Db 2281 tagtgccgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2340		
QY 2683 gacagacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2722		
Db 2341 gacagacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2380		
RESULT 8				
AA207114				
ID AA207114	standard; cDNA;	2351	BP.	
XX				
AC AA207114;				
XX				
DT 08-OCT-1999	(first entry)			
XX				
DE Human vanilloid receptor homologue VANILREP2 encoding cDNA.				
XX				
KW Human; vanilloid receptor homologue; VANILREP2; polymorphic variant; PVR-1; therapy; diagnosis; chronic pain; neuropathic; postoperative; rheumatoid arthritis; neuralgia; algisia; nerve injury; ischaemia; neurodegeneration; stroke; incontinence; and inflammatory disorders.				
XX				
OS Homo sapiens.				
XX				
Key	Location/Qualifiers			
FT CDS	5..2299			
FT	/*tag= a			
FT	/product= "VANILREP2"			
FT	/note= "vanilloid receptor homologue"			
XX				
PN W0937765-A1.				
XX				
PD 29-JUL-1999.				
XX				
PF 25-JAN-1999;	99NC-EP00420.			
XX				
PR 20-JAN-1999;	99GB-0001209.			
PR	27-JAN-1998;	98EP-0300549.		
PR	26-OCT-1998;	98GB-0023421.		
PA (SMK) SMITHKLINE BEECHAM PLC.				
XX				
PI Davis JB, Duckworth DM, Hayes PD;				
XX				
DR WPI: 1999-479049/40.				
DR P-PSDB; AAY29469.				
PT New human vanilloid receptor homologues (VANILREP2)				
XX				
PS Claim 9; Page 29-30; 47pp; English.				
XX				
CC The present sequence encodes a human vanilloid receptor homologue, designated VANILREP2. VANILREP2 can be used to diagnose disease or susceptibility to disease related to expression or activity of VANILREP2 polypeptides. VANILREP2 may be used to treat diseases including pain, (for example chronic, neuropathic, postoperative, rheumatoid arthritis), neuralgia, algisia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence, and inflammatory disorders.				
CC Sequence 2351 BP; 486 A; 684 C; 676 G; 505 T; 0 other;				
SQ				
Query	Match	Score	DB	Length
QY 2503 gaaacgacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	83.6%; Best Local Similarity	2347.8;	DB 20;	Length 2351;
Db 2161 gagacgacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.9%; Matches	2249;	Pred. No. 0;	Conservative
QY 2663 gaaacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2240	Mismatches	2;
Db 2221 gagacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2280	Indels	0;
QY 2623 tagtgccgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2682	Gaps	0;
Db 2281 tagtgccgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2340		
QY 2683 gacagacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2722		
Db 2341 gacagacgtgtccatgtgtggatggccgtcaaggccgggtgtccctcgaaactctc	90.0%;	2380		
RESULT 8				
AA207114				
ID AA207114	standard; cDNA;	2351	BP.	
XX				
AC AA207114;				
XX				
DT 08-OCT-1999	(first entry)			
XX				
DE Human vanilloid receptor homologue VANILREP2 encoding cDNA.				
XX				
KW Human; vanilloid receptor homologue; VANILREP2; polymorphic variant; PVR-1; therapy; diagnosis; chronic pain; neuropathic; postoperative; rheumatoid arthritis; neuralgia; algisia; nerve injury; ischaemia; neurodegeneration; stroke; incontinence; and inflammatory disorders.				
XX				
OS Homo sapiens.				
XX				
Key	Location/Qualifiers			
FT CDS	5..2299			
FT	/*tag= a			
FT	/product= "VANILREP2"			
FT	/note= "vanilloid receptor homologue"			
XX				
PN W0937765-A1.				
XX				
PD 29-JUL-1999.				
XX				
PF 25-JAN-1999;	99NC-EP00420.			
XX				
PR 20-JAN-1999;	99GB-0001209.			
PR	27-JAN-1998;	98EP-0300549.		
PR	26-OCT-1998;	98GB-0023421.		
PA (SMK) SMITHKLINE BEECHAM PLC.				
XX				
PI Davis JB, Duckworth DM, Hayes PD;				
XX				
DR WPI: 1999-479049/40.				
DR P-PSDB; AAY29469.				
PT New human vanilloid receptor homologues (VANILREP2)				
XX				
PS Claim 9; Page 29-30; 47pp; English.				
XX				
CC The present sequence encodes a human vanilloid receptor homologue, designated VANILREP2. VANILREP2 can be used to diagnose disease or susceptibility to disease related to expression or activity of VANILREP2 polypeptides. VANILREP2 may be used to treat diseases including pain, (for example chronic, neuropathic, postoperative, rheumatoid arthritis), neuralgia, algisia				

